US20050074504A1 - Use of borate-polyol complexes in ophthalmic compositions - Google Patents

Use of borate-polyol complexes in ophthalmic compositions Download PDF

Info

Publication number
US20050074504A1
US20050074504A1 US10/996,501 US99650104A US2005074504A1 US 20050074504 A1 US20050074504 A1 US 20050074504A1 US 99650104 A US99650104 A US 99650104A US 2005074504 A1 US2005074504 A1 US 2005074504A1
Authority
US
United States
Prior art keywords
polyol
borate
water
composition
method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/996,501
Inventor
Masood Chowhan
Nissanke Dassanayake
Original Assignee
Masood Chowhan
Dassanayake Nissanke L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US87943592A priority Critical
Priority to US08/118,833 priority patent/US5342620A/en
Priority to US08/198,427 priority patent/US5505953A/en
Priority to US08/479,281 priority patent/US5811466A/en
Priority to US09/109,453 priority patent/US6143799A/en
Priority to US09/597,310 priority patent/US6365636B1/en
Priority to US10/027,998 priority patent/US6503497B2/en
Priority to US10/302,294 priority patent/US6849253B2/en
Application filed by Masood Chowhan, Dassanayake Nissanke L. filed Critical Masood Chowhan
Priority to US10/996,501 priority patent/US20050074504A1/en
Publication of US20050074504A1 publication Critical patent/US20050074504A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26816788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20050074504(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S134/00Cleaning and liquid contact with solids
    • Y10S134/901Contact lens
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/81Addiction
    • Y10S514/812Narcotic
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/839Contact lens treatment
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/839Contact lens treatment
    • Y10S514/84Chemical sterilizing
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/912Ophthalmic
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/912Ophthalmic
    • Y10S514/915Wetting agent

Abstract

Water-soluble borate-polyol complexes are useful as buffers and/or antimicrobials in aqueous ophthalmic compositions, including those containing polyvinyl alcohol. These compositions have greater antimicrobial activity than comparable compositions containing typical borate buffers and unexpectedly increase the antimicrobial efficacy of other antimicrobial agents when used in combination. In addition, use of the borate-polyol complexes avoids the incompatibility problem typically associated with the combination of borate buffer and polyvinyl alcohol; therefore, the compositions disclosed herein may also contain polyvinyl alcohol.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • The present application is a continuation of U.S. patent application Ser. No. 10/302,294 (allowed), which is a continuation of U.S. patent application Ser. No. 10/027,998 (now U.S. Pat. No. 6,503,497), which is a continuation of U.S. patent application Ser. No. 09/597,310 (now U.S. Pat. No. 6,365,636), which is a continuation of U.S. patent application Ser. No. 09/109,453 (now U.S. Pat. No. 6,143,799), which is a divisional of U.S. patent application Ser. No. 08/479,281 (now U.S. Pat. No. 5,811,466), which is a divisional of U.S. patent application Ser. No. 08/198,427 (now U.S. Pat. No. 5,505,953), which is a continuation-in-part of U.S. patent application Ser. No. 08/118,833 (now U.S. Pat. No. 5,342,620), which is a continuation of U.S. patent application Ser. No. 07/879,435 (now abandoned).
  • BACKGROUND OF THE INVENTION
  • This invention relates to the use of borate-polyol complexes in ophthalmic compositions. In particular, these complexes are useful as buffers and/or antimicrobial agents in aqueous ophthalmic compositions, including those ophthalmic compositions containing polyvinyl alcohol.
  • Ophthalmic compositions are generally formulated to have a pH between about 4.0 and 8.0. To achieve a pH in this range and to maintain the pH for optimal stability during the shelf life of the composition, a buffer is often included. Borate is the buffer of choice for use in ophthalmic compositions, since it has some inherent antimicrobial activity and often enhances the activity of antimicrobials; however, when polyvinyl alcohol (PVA) is also an ingredient in the composition, borate and PVA form a water-insoluble complex which precipitates out of solution and acts as an irritant in the eye. This incompatibility of borate and PVA in contact lens solutions is well-known, and has been discussed, for example, in an article by P. L. Rakow in Contact Lens Forum, (June 1988), pages 41-46. Moreover, borate buffer cannot be effectively used below pH 7.0 due to its low buffering capacity to lower pH.
  • Since borate is incompatible with PVA, ophthalmic compositions containing PVA are generally buffered with acetate, phosphate or other buffers. There are disadvantages to using these alternative buffers: for example, acetate is a weak buffer (pKa of about 4.5), so a relatively large amount is needed; on the other hand, phosphate is a good buffer but, when used in concentrations generally found in ophthalmic formulations, it reduces the antimicrobial activity of preservatives.
  • It is well known that small organic compounds, such as benzalkonium chloride (BAC), chlorhexidine, thimerosal have excellent antimicrobial activity; however, it is now known that these small organic antimicrobials are often toxic to the sensitive tissues of the eye and can accumulate in contact lenses, particularly soft, hydrophilic contact lenses. More recently, polymeric antimicrobials such as Polyquad® (polyquaternium-1) and Dymed® (polyhexamethylene biguanide) have been used in contact lens care products as disinfectants and preservatives. While these polymeric antimicrobials exhibit a broad spectrum of antimicrobial activity, they generally have relatively weak antifungal activity, especially against Aspergillus niger and Aspergillus fumigatus.
  • A need therefore exists for ophthalmic compositions which have an optimal pH for stability and efficacy, but whose antimicrobial efficacy is not compromised.
  • SUMMARY OF THE INVENTION
  • This invention provides such ophthalmic compositions. The ophthalmic compositions of the present invention comprise borate-polyol complexes which have surprisingly been found to have increased antimicrobial activity as compared to boric acid or its salts, particularly with respect to organisms such as A. niger. Moreover, these complexes unexpectedly increase the antimicrobial efficacy of other antimicrobial agents when used in combination.
  • The borate-polyol complexes are formed by mixing boric acid and/or its salts with polyols, such as mannitol, glycerin or propylene glycol, in an aqueous solution. The resultant solution may then be used as a buffer and/or antimicrobial agent in aqueous ophthalmic compositions, even where such compositions also contain PVA. The borate-polyol complexes of the present invention are also useful in unpreserved saline solutions.
  • The borate-polyol complexes of the present invention are particularly useful as adjunctive disinfecting agents in contact lens disinfecting solutions containing monomeric quaternary ammonium compounds (e.g., benzalkonium chloride) or biguanides (e.g., chlorhexidine) or polymeric antimicrobials, such as polymeric quaternary ammonium compounds (e.g., Polyquad®, Alcon Laboratories, Inc., Fort Worth, Tex.) or polymeric biguanides (e.g., Dymed®, Bausch & Lomb, Rochester, N.Y.).
  • The compositions of the present invention may optionally contain PVA; such compositions are particularly useful in contact lens care products which are targeted for wearers of rigid gas-permeable contact lenses (RGPs), who often complain of discomfort. PVA is a viscosity enhancer and is used extensively in all types of RGP products in order to improve the comfort and wearing time of RGPs. PVA is also extensively used as a viscosity enhancer for pharmaceutical ophthalmic compositions such as eye drops, gels or ocular inserts.
  • DETAILED DESCRIPTION OF THE INVENTION
  • As used herein, the term “borate” shall refer to boric acid, salts of boric acid and other pharmaceutically acceptable borates, or combinations thereof. Most suitable are: boric acid, sodium borate, potassium borate, calcium borate, magnesium borate, manganese borate, and other such borate salts.
  • As used herein, and unless otherwise indicated, the term “polyol” shall refer to any compound having at least two adjacent —OH groups which are not in trans configuration relative to each other. The polyols can be linear or circular, substituted or unsubstituted, or mixtures thereof, so long as the resultant complex is water-soluble and pharmaceutically acceptable. Such compounds include sugars, sugar alcohols, sugar acids and uronic acids. Preferred polyols are sugars, sugar alcohols and sugar acids, including, but not limited to: mannitol, glycerin, propylene glycol and sorbitol. Especially preferred polyols are mannitol and glycerin; most preferred is mannitol.
  • The water-soluble borate-polyol complexes of the present invention may be formed by mixing borate with the polyol(s) of choice in an aqueous solution. These complexes can be used in conjunction with other known preservatives and disinfectants to meet preservative efficacy and disinfection standards. In such compositions, the molar ratio of borate to polyol is generally between about 1:1 and about 1:10, and is preferably between about 1:1 and about 1:2.5.
  • The borate-polyol complexes may also be used in unpreserved salines to meet preservative efficacy standards. In these unpreserved salines, the molar ratio of borate to polyol is generally between about 1:0.1 and about 1:1, and is especially between about 1:0.25 and about 1:0.75. Some borate-polyol complexes, such as potassium borotartrate, are commercially available.
  • The borate-polyol complexes are utilized in the compositions of the present invention in an amount between about 0.5 to about 6.0 percent by weight (wt %), preferably between about 1.0 to about 2.5 wt %. The optimum amount, however, will depend upon the complexity of the product, since potential interactions may occur with the other components of a composition. Such optimum amount can be readily determined by one skilled in the formulatory arts.
  • The compositions of the present invention useful with RGPs or compositions such as eye drops, gels or ocular inserts will preferably also contain PVA or other viscosity-enhancing polymers, such as cellulosic polymers or carboxy vinyl polymers. PVA is available in a number of grades, each differing in degree of polymerization, percent of hydrolysis, and residual acetate content. Such differences affect the physical and chemical behavior of the different grades. PVA can be divided into two broad categories, i.e., completely hydrolyzed and partially hydrolyzed. Those containing 4% residual acetate content or less are referred to as completely hydrolyzed. Partially hydrolyzed grades usually contain 20% or more residual acetate. The molecular weight of PVA's vary from 20,000 to 200,000. In general, PVA used in ophthalmic products has an average molecular weight in the range of 30,000 to 100,000 with 11% to 15% residual acetate. Compositions of the present invention generally contain such types of PVA at a concentration less than about 10.0 wt %, preferably between about 0.1 and about 1.4 wt % and most preferably at a concentration of about 0.75 wt %.
  • EXAMPLE 1
  • The water-soluble borate-polyol complexes of the present invention may be prepared as illustrated below. FORMULATION (% weight/volume) INGREDIENT A B C D E F G H Boric acid 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35 Sodium 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 borate Mannitol 0.5 1.0 1.5 2.0 Glycerin 0.5 1.0 1.5 2.0 Na2EDTA 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Purified q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. water HCl/NaOH pH 7.4 pH 7.4 pH 7.4 pH 7.4 pH 7.4 pH 7.4 pH 7.4 pH 7.4 Polyquad ® 0.001 + 10% 0.001 + 10% 0.001 + 10% 0.001 + 10% 0.001 + 10% 0.001 + 10% 0.001 + 10% 0.001 + 10% xs xs xs xs xs xs xs xs

    Preparation:
  • Formulations A-H were prepared as follows. Tubular, labeled and calibrated 150 milliliter (mL) beakers were each filled with about 90 mL of purified water. Boric acid, sodium borate and mannitol or glycerin were then added and dissolved by stirring the solution for about 25 minutes. At this time, disodium EDTA (ethylene diamine tetraacetic acid) was added with stirring. Purified water was added to bring the solutions almost to 100% (100 mL), pH was adjusted to approximately 7.4 and the osmolality was measured. Polyquad® was then added and the volume brought to 100% by the addition of purified water. pH was again measured and adjusted, if necessary, and the osmolality was measured again.
  • It is not always necessary to have an isotonic solution; however, if there is a need to have an isotonic solution, the osmolality can be adjusted by incorporating polyol with OH groups in trans position, sodium chloride, potassium chloride, calcium chloride or other osmolality building agents which are generally acceptable in ophthalmic formulations and known to those skilled in the art.
  • EXAMPLE 2
  • Aqueous ophthalmic compositions of the present invention may be prepared using the formulations illustrated below. FORMULATION (percent by weight) INGREDIENT 1 2 3 4 5 6 7 8 9 PVA 0.75 1.4 0.75 0.75 0.75 0.75 0.75 0.75 0.75 Hydroxyethyl cellulose 0.75 0.28 0.28 0.28 0.28 0.75 0.75 (HEC) Mannitol 2.0 2.0 2.0 2.0 2.0 2.0 0.5 2.0 2.0 Boric acid 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35 Sodium borate 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 Edetate disodium 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Sodium chloride 0.09 0.09 0.09 0.09 0.45 0.09 0.09 0.09 0.09 Polyquad ® 0.001 0.001 0.001 0.001 0.001 0.001 0.001 Sucrose 2.5 2.5 2.5 Polyhexamethylene 0.0005 biguanide BAC 0.004

    Preparation:
  • Formulations 1-9 were prepared as follows. A first solution (Solution A) was prepared by adding 500 mL of warm purified water to a calibrated two liter aspirator bottle equipped with a magnetic stirrer. PVA and hydroxyethyl cellulose were then added to Solution A and the contents dispersed by stirring. After dispersal of the polymers, a filter assembly was attached to the aspirator bottle (142 mm Millipore filter holder with 0.2 l filter), and this whole apparatus autoclaved at 121° C. for 30 minutes. Solution A with the filter assembly attached was then allowed to cool to room temperature with stirring. A second solution (Solution B), was prepared in a 500 mL beaker containing 300 mL of purified water by adding boric acid, sodium borate and mannitol and dissolving the contents by stirring for 25 minutes. Edetate disodium, sodium chloride, preservatives and other osmolality-building agents, as necessary, were added to Solution B and the contents dissolved with stirring. Solution B was then sterile filtered into the aspirator bottle containing Solution A. The pH of the resultant solution was then adjusted and the volume brought to 100% by sterile filtering purified water.
  • EXAMPLE 3
  • The following ophthalmic compositions of the present invention may also be prepared using the procedure detailed in Example 2. FORMULATION (percent by weight) INGREDIENT 10 11 12 13 14 15 16 17 18 19 PVA 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 Naphazolene HCl 0.1 0.1 Sodium 10.0 sulfacetamide Fluorometholone 0.1 Gentamycin sulfate 0.4 Levobunolol HCl 0.5 Mydrysone 1.0 Pilocarpine nitrate 1.0 1.0 1.0 Sodium 0.4 metabisulfite Mannitol 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 4.0 0.5 Boric acid 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.5 Sodium borate 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 Sodium chloride 0.45 0.45 0.45 0.45 0.45 0.45 0.45 Edetate disodium 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 BAC 0.004 Polyquad ® 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001
  • EXAMPLE 4
  • The following is a typical wetting and soaking composition of the present invention for use with RGPs. INGREDIENT AMOUNT (wt %) PVA 0.75 HEC 0.38 Boric acid 0.35 Sodium borate 0.11 Mannitol 2.0 Potassium chloride 0.038 Magnesium chloride 0.02 Calcium chloride 0.0154 Sodium chloride 0.09 Polysorbate 80 0.005 Polyquad ® 0.001 NaOH and/or HCl pH 7.4 Purified water q.s.

    Preparation:
  • In a suitable container containing approximately 30% of the final volume of purified water, PVA and HEC were added and dispersed. This solution was then autoclaved. The solution was allowed to cool to room temperature with stirring. In a separate container, containing approximately 50% of the final volume of purified water, boric acid and sodium borate were added, and dissolved, followed by mannitol. This second solution was then stirred for about 30 minutes, then potassium chloride, calcium chloride, magnesium chloride, sodium chloride, polysorbate 80 and Polyquad® were added, with stirring. The second solution was then added to the first solution via a 0.2 i filter. Last, the pH was adjusted to 7.4 and the volume brought to 100% with purified water.
  • EXAMPLE 5
  • The following is a typical daily cleaner composition of the present invention for use with RGPs and may be prepared in a manner similar to that detailed in Example 4. INGREDIENT AMOUNT (wt %) Nylon 1111 2.50 Dextran 70 6.0 Sodium borate 0.25 Boric acid 0.50 Miracare ® 2MCA 0.50 PDMA-1 0.15 Propylene glycol 10.0 Polyquad ® 0.0055 EDTA 0.10 Mannitol 1.20 NaOH and/or HCl pH 7.4 Purified water q.s.
  • EXAMPLE 6
  • The following is a typical wetting and soaking composition of the present invention which may be prepared in a manner similar to that detailed in Example 4. INGREDIENT AMOUNT (wt %) Hydroxypropyl 0.72 methylcellulose (Methocel ® E4M) Mannitol 1.0 Sodium borate 0.11 Boric acid 0.35 Sodium chloride 0.19 Polyquad ® 0.0011 EDTA 0.10 NaOH and/or HCl pH 7.4 Purified water q.s.
  • EXAMPLE 7
  • The following is a typical comfort drop composition of the present invention which may be prepared in a manner similar to that detailed in Example 4. INGREDIENT AMOUNT (w/v %) PVA 0.75 HEC 0.28 Mannitol 2.0 Sodium borate 0.11 Boric acid 0.35 Sodium chloride 0.152 Polyquad ® 0.00082 EDTA 0.10 NaOH and/or HCl pH 7.4 Purified water q.s.
  • EXAMPLE 8
  • The following is a typical RGP cleaner composition of the present invention which may be prepared in a manner similar to that detailed in Example 4. INGREDIENT AMOUNT (wt %) French Naturelle ® ES (Nylon 2.5 11) Hydroxyethyl cellulose 0.4 Sodium borate, decahydrate 0.25 Boric acid 0.50 Mannitol 3.5 Miracare ® 2MCA) 0.50 Isopropyl alcohol (v/v) 10.0 NaOH and/or HCl q.s. 7.4 Purified water q.s.
  • EXAMPLE 9
  • The following is a typical RGP wetting and/or soaking composition of the present invention, which may be prepared in a manner similar to that detailed in Example 4. INGREDIENT AMOUNT (wt %) Methocel ® E4M 0.85 Mannitol 2.00 Sodium borate 0.11 Boric acid 0.35 Sodium chloride 0.19 Disodium edetate 0.1 Polyquad ® 0.001 NaOH and/or HCl pH 7.4 Purified water q.s.
  • EXAMPLE 10
  • The following study compared the antimicrobial preservative efficacy of two wetting, soaking and disinfecting solutions: one containing phosphate buffer (Formulation A); and the other containing a borate-polyol complex of the present invention (Formulation B).
  • Formulations A and B are shown in the following table. FORMULATION (wt %) INGREDIENT A B PVA 0.75 0.75 HEC 0.5 0.5 Sodium phosphate 0.67 Sodium biophosphate 0.017 Boric acid 0.35 Sodium borate 0.11 Mannitol 2.0 Disodium edetate 0.1 0.1 Sodium chloride 0.458 0.153 Polysorbate 80 0.005 0.005 Benzalkonium chloride 0.01 0.01 Purified water q.s. q.s.
  • Formulations A and B were tested against FDA challenge organisms. The log reductions after 1 hour are tabulated below: FORMULATION (log reduction) TEST ORGANISM A B A. niger 2.1 4.4 B. albicans 4.0 5.3 P. aeruginosa 5.3 5.3 S. aureus 5.5 5.2 E. coli 5.5 5.5

    The results shown above indicate that Formulation B (containing borate-polyol complex) has a broader spectrum of activity than Formulation A (containing phosphate buffer), and has greater activity against certain organisms, such as A. niger.
  • EXAMPLE 11
  • The following study compared the antimicrobial preservative efficacy of two unpreserved saline solutions identical except that one contained a borate-polyol complex of the present invention (Formulation C) and the other contained the conventional borate buffer (Formulation D).
  • An organism challenge approach based on the British Pharmacopoeia (“BP”) 1988 Test for Efficacy of Preservatives in Pharmaceutical Products was used to evaluate the antimicrobial preservative efficacy of Formulations C and D. Formulation samples were inoculated with known levels of A. niger and sampled at predetermined intervals to determine if the system was capable of killing or inhibiting the propagation of organisms introduced into the products.
  • Formulations C and D are shown in the following table. FORMULATION (wt %) INGREDIENT C D Boric acid 1.0 1.0 Sodium borate 0.2 0.2 Mannitol 1.5 Sodium chloride 0.3 Disodium edetate 0.1 0.1 NaOH and/or HCl pH 7.4 pH 7.4 Purified water q.s. q.s.
  • The results indicated that there was a 3.1 log reduction of A. niger with Formulation C and only 1.2 log reduction with Formulation D after 7 days. Formulation C met the BP standards for preservative efficacy against A. niger, while Formulation D failed to meet the BP standards.
  • EXAMPLE 12
  • The following study compared the antimicrobial preservative efficacy of two disinfecting solutions identical except that one contained a borate-polyol complex of the present invention (Formulation E) and the other contained the conventional borate buffer (Formulation F).
  • An organism challenge approach based on the BP 1988 Test for Efficacy of Preservatives in Pharmaceutical Products was used to evaluate the antimicrobial preservative efficacy of Formulations E and F. Formulation samples were inoculated with known levels of A. niger and sampled at predetermined intervals to determine if the system was capable of killing or inhibiting the propagation of organisms introduced into the products.
  • Formulations E and F are shown in the following table. FORMULATION (wt %) INGREDIENT E F Boric acid 0.3 0.35 Sodium borate 0.11 0.11 Mannitol 0.85 Sodium citrate 0.56 0.56 Citric acid 0.021 0.21 Sodium chloride 0.48 0.48 Pluronic P103 0.5 0.5 Disodium edetate 0.05 0.05 Polyquad ® 0.001 0.001 NaOH and/or HCl pH 7.0 pH 7.0 Purified water q.s. q.s.
  • The results indicate that there was a 2.1 log reduction of A. niger with Formulation E and only 1.1 log reduction with Formulation F after 7 days. Formulation E met the BP standards for preservative efficacy against A. niger, while Formulation F failed to meet the BP standards.
  • The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.

Claims (24)

1. An aqueous ophthalmic composition comprising between about 0.5 and about 6.0 wt % of a water-soluble borate-polyol complex.
2. The aqueous composition of claim 1, wherein the water-soluble borate-polyol complex is present at a concentration between about 1.0 and 2.5 wt %.
3. The aqueous composition of claim 1, wherein the water-soluble borate-polyol complex comprises borate and polyol in a molar ratio between about 1:0.1 and about 1:10.
4. The aqueous composition of claim 3, wherein the water-soluble borate-polyol complex comprises borate and polyol in a molar ratio between about 1:0.25 and about 1:2.5.
5. The aqueous composition of claim 1, wherein the water-soluble borate-polyol complex comprises a polyol selected from the group consisting of sugars, sugar alcohols and sugar acids.
6. The aqueous composition of claim 2, wherein the polyol is selected from the group consisting of mannitol, glycerin, propylene glycol and sorbitol.
7. The aqueous composition of claim 6, wherein the polyol is selected from the group consisting of mannitol and glycerin.
8. The aqueous composition of claim 7, wherein the polyol is mannitol.
9. The aqueous composition of claim 1, further comprising less than or equal to about 10 wt % of a viscosity-enhancing polymer selected from the group consisting of: polyvinyl alcohol, cellulosic polymers, and carboxy vinyl polymers.
10. The aqueous composition of claim 9, wherein the viscosity-enhancing polymer comprises polyvinyl alcohol.
11. The aqueous composition of claim 9, wherein the polyvinyl alcohol is present at a concentration between about 0.1 and about 1.4 wt %.
12. The aqueous composition of claim 1, further comprising an ophthalmically acceptable antimicrobial agent.
13. The aqueous composition of claim 1, wherein the ophthalmically acceptable antimicrobial agent is selected from the group consisting of: monomeric and polymeric quaternary ammonium compounds and their ophthalmically acceptable salts, monomeric and polymeric biguanides and their ophthalmically acceptable salts, and combinations thereof.
14. A method of preparing an aqueous ophthalmic composition, comprising the steps of preparing a water-soluble borate-polyol complex by mixing borate and a polyol together in an aqueous solvent and adding polyvinyl alcohol thereto.
15. The method of claim 14, wherein the water-soluble borate-polyol complex comprises borate and polyol in a molar ratio between about 1:0.1 and about 1:10.
16. The method of claim 15, wherein the water-soluble borate-polyol complex comprises borate and polyol in a molar ratio between about 1:0.25 and about 1:2.5.
17. The method of claim 14, wherein the concentration of the water-soluble borate-polyol complex in the final composition is between about 0.5 and about 3.0 wt %.
18. The method of claim 17, wherein the concentration of the water-soluble borate-polyol complex in the final composition is between about 1.0 and about 2.0 wt %.
19. The method of claim 14, wherein the water-soluble borate-polyol complex comprises a polyol selected from the group consisting of sugars, sugar alcohols and sugar acids.
20. The method of claim 19, wherein the polyol is selected from the group consisting of mannitol, glycerin, propylene glycol and sorbitol.
21. The method of claim 20, wherein the polyol is selected from the group consisting of mannitol and glycerin.
22. The method of claim 21, wherein the polyol is mannitol.
23. A method for buffering an aqueous ophthalmic composition by adding a water-soluble borate-polyol complex to the composition.
24. A method for imparting antimicrobial activity to an ophthalmic composition by adding a water-soluble borate-polyol complex to the composition.
US10/996,501 1992-05-06 2004-11-23 Use of borate-polyol complexes in ophthalmic compositions Abandoned US20050074504A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US87943592A true 1992-05-06 1992-05-06
US08/118,833 US5342620A (en) 1992-05-06 1993-09-07 Use of borate-polyol complexes in ophthalmic compositions
US08/198,427 US5505953A (en) 1992-05-06 1994-02-22 Use of borate-polyol complexes in ophthalmic compositions
US08/479,281 US5811466A (en) 1992-05-06 1995-06-07 Use of borate-polyol complexes in ophthalmic compositions
US09/109,453 US6143799A (en) 1992-05-06 1998-07-02 Use of borate-polyol complexes in ophthalmic compositions
US09/597,310 US6365636B1 (en) 1992-05-06 2000-06-20 Use of borate-polyol complexes in ophthalmic compositions
US10/027,998 US6503497B2 (en) 1992-05-06 2001-12-19 Use of borate-polyol complexes in ophthalmic compositions
US10/302,294 US6849253B2 (en) 1992-05-06 2002-11-22 Use of borate-polyol complexes in ophthalmic compositions
US10/996,501 US20050074504A1 (en) 1992-05-06 2004-11-23 Use of borate-polyol complexes in ophthalmic compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/996,501 US20050074504A1 (en) 1992-05-06 2004-11-23 Use of borate-polyol complexes in ophthalmic compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/302,294 Continuation US6849253B2 (en) 1992-05-06 2002-11-22 Use of borate-polyol complexes in ophthalmic compositions

Publications (1)

Publication Number Publication Date
US20050074504A1 true US20050074504A1 (en) 2005-04-07

Family

ID=26816788

Family Applications (7)

Application Number Title Priority Date Filing Date
US08/198,427 Expired - Lifetime US5505953A (en) 1992-05-06 1994-02-22 Use of borate-polyol complexes in ophthalmic compositions
US08/479,281 Expired - Lifetime US5811466A (en) 1992-05-06 1995-06-07 Use of borate-polyol complexes in ophthalmic compositions
US09/109,453 Expired - Lifetime US6143799A (en) 1992-05-06 1998-07-02 Use of borate-polyol complexes in ophthalmic compositions
US09/597,310 Expired - Fee Related US6365636B1 (en) 1992-05-06 2000-06-20 Use of borate-polyol complexes in ophthalmic compositions
US10/027,998 Expired - Fee Related US6503497B2 (en) 1992-05-06 2001-12-19 Use of borate-polyol complexes in ophthalmic compositions
US10/302,294 Expired - Fee Related US6849253B2 (en) 1992-05-06 2002-11-22 Use of borate-polyol complexes in ophthalmic compositions
US10/996,501 Abandoned US20050074504A1 (en) 1992-05-06 2004-11-23 Use of borate-polyol complexes in ophthalmic compositions

Family Applications Before (6)

Application Number Title Priority Date Filing Date
US08/198,427 Expired - Lifetime US5505953A (en) 1992-05-06 1994-02-22 Use of borate-polyol complexes in ophthalmic compositions
US08/479,281 Expired - Lifetime US5811466A (en) 1992-05-06 1995-06-07 Use of borate-polyol complexes in ophthalmic compositions
US09/109,453 Expired - Lifetime US6143799A (en) 1992-05-06 1998-07-02 Use of borate-polyol complexes in ophthalmic compositions
US09/597,310 Expired - Fee Related US6365636B1 (en) 1992-05-06 2000-06-20 Use of borate-polyol complexes in ophthalmic compositions
US10/027,998 Expired - Fee Related US6503497B2 (en) 1992-05-06 2001-12-19 Use of borate-polyol complexes in ophthalmic compositions
US10/302,294 Expired - Fee Related US6849253B2 (en) 1992-05-06 2002-11-22 Use of borate-polyol complexes in ophthalmic compositions

Country Status (1)

Country Link
US (7) US5505953A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229219A1 (en) * 2005-04-11 2006-10-12 Advanced Medical Optics, Inc. Borate-polyol mixtures as a buffering system
US20070297990A1 (en) * 2006-06-27 2007-12-27 Shah Mandar V Self-preserving composition
US20080287672A1 (en) * 2007-05-16 2008-11-20 Uday Doshi Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods
US9579341B2 (en) 2007-05-16 2017-02-28 Johnson & Johnson Consumer Inc. Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
KR100390692B1 (en) 1993-12-29 2003-09-29 바슈 앤드 롬 인코포레이티드 Carbohydrate composition and method for contact lens cleaning and disinfecting
CA2272308C (en) 1996-12-13 2007-01-16 Alcon Laboratories, Inc. Use of low molecular weight amino alcohols in ophthalmic compositions
PT970175E (en) 1997-07-29 2003-02-28 Alcon Lab Inc Conditioning solutions for caring for rigid contact lenses
WO1999024541A1 (en) * 1997-11-12 1999-05-20 Bausch & Lomb Incorporated Cleaning and disinfecting contact lenses with a biguanide and a phosphate-borate buffer
US20030129083A1 (en) * 1997-11-26 2003-07-10 Advanced Medical Optics, Inc. Multi purpose contact lens care compositions including propylene glycol or glycerin
US6790816B2 (en) 1999-09-24 2004-09-14 Bausch & Lomb Incorporated High osmolyte cleaning and disinfection method and solution for contact lenses
WO2001097852A1 (en) * 2000-06-19 2001-12-27 Santen Pharmaceutical Co., Ltd. Aseptics
AR035509A1 (en) 2000-12-21 2004-06-02 Alcon Inc Improved artificial tears solution containing a combination of three demulcents and use of said solution for the manufacture of a medicament
CA2435146C (en) 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
US20050002970A1 (en) * 2001-12-21 2005-01-06 Ketelson Howard Allen Inorganic nanopartices to modify the viscosity and physical properties of ophthalmic and otic compositions
JP4580649B2 (en) * 2001-12-21 2010-11-17 アルコン、インコーポレイテッド Method of using nanoparticles in ophthalmic compositions as a biocide carrier
US20050003014A1 (en) * 2001-12-21 2005-01-06 Ketelson Howard Allen Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs
US6586477B1 (en) 2002-10-31 2003-07-01 Sporicidin Company Teat dip composition containing phenol and phenate
TWI335819B (en) * 2002-12-24 2011-01-11 Alcon Inc Use of oculosurface selective glucocorticoid in the treatment of dry eye
WO2004103183A2 (en) * 2003-05-21 2004-12-02 Dietrich Rene H Ultrasound coupling medium for use in medical diagnostics
US7195063B2 (en) * 2003-10-15 2007-03-27 Schlumberger Technology Corporation Downhole sampling apparatus and method for using same
US20050118129A1 (en) * 2003-12-01 2005-06-02 Erning Xia Gentle and enhanced preservative systems
US20050118132A1 (en) * 2003-12-01 2005-06-02 Erning Xia Nonionic surfactant containing compositions for cleaning contact lenses
US6936640B2 (en) * 2003-12-04 2005-08-30 Alcon, Inc. Biguanide/quaternary ammonium containing copolymeric biocides and use thereof in pharmaceutical compositions
WO2005060953A1 (en) * 2003-12-09 2005-07-07 Alcon, Inc. Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions
ES2561034T3 (en) 2003-12-09 2016-02-24 Novartis Ag Use of bis-amines to increase the antimicrobial activity of aqueous compositions
AU2004305539B2 (en) * 2003-12-11 2010-09-02 Alcon, Inc. Ophthalmic compositions containing a polysaccharide/borate gelling system
US20070059274A1 (en) * 2004-12-01 2007-03-15 Bahram Asgharian Ophthalmic compositions containing a PVA/borate gelling system
US20050129770A1 (en) * 2003-12-11 2005-06-16 Alcon, Inc. Ophthalmic compositions containing a PVA/borate gelling system
US7022740B2 (en) * 2004-04-29 2006-04-04 Leonard Mackles Lubricious ophthalmic solutions
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
US20060141059A1 (en) * 2004-12-27 2006-06-29 Alcon, Inc. Self-preserved ophthalmic pharmaceutical compositions containing tobramycin
JP5108234B2 (en) * 2005-02-07 2012-12-26 日本特殊陶業株式会社 Micro heater and sensor
US20070053948A1 (en) * 2005-09-08 2007-03-08 Bausch & Lomb Incorporated Lens care solution demonstration kit
US20070148099A1 (en) * 2005-12-27 2007-06-28 Burke Susan E Use of aroma compounds as defoaming agents for ophthalmic solutions with high concentrations of surfactants
TWI394564B (en) * 2006-09-21 2013-05-01 Alcon Res Ltd Self-preserved aqueous pharmaceutical compositions
WO2008036855A2 (en) * 2006-09-21 2008-03-27 Alcon Research, Ltd. Self-preserved aqueous pharmaceutical compositions
JP5394927B2 (en) * 2006-09-28 2014-01-22 アルコン リサーチ, リミテッド Self-preserving aqueous pharmaceutical composition
US20080095754A1 (en) * 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions comprising diglycine
US8138156B2 (en) * 2006-10-18 2012-03-20 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US7897553B2 (en) 2006-10-23 2011-03-01 Bausch & Lomb Incorporated Biguanide composition with low terminal amine
TWI434926B (en) * 2006-12-11 2014-04-21 Alcon Res Ltd Use of peo-pbo block copolymers in ophthalmic compositions
US20080214421A1 (en) * 2007-02-19 2008-09-04 Fang Zhao Contact lens care composition
WO2008131499A1 (en) * 2007-04-26 2008-11-06 Realco Sa Method for treating banana leafspot disease and treatment composition
GB0718435D0 (en) * 2007-09-21 2007-10-31 Northern Health And Social Car Wpund care formulation
ES2644550T3 (en) * 2008-03-17 2017-11-29 Novartis Ag Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI544927B (en) 2008-03-17 2016-08-11 愛爾康研究有限公司 Pharmaceutical compositions having low concentration of surfactants for promoting bioavailability of therapeutic agents
US8629099B2 (en) * 2008-03-25 2014-01-14 Bausch & Lomb Incorporated Ophthalmic compositions comprising a dipeptide
TWI454289B (en) * 2008-04-03 2014-10-01 Alcon Res Ltd Use of cis-diol-containing polymer to inhibit the uptake of cationic biocides into hydrogel biomaterials
US20090270345A1 (en) * 2008-04-26 2009-10-29 Alcon Research, Ltd. Polymeric artificial tear system
CA2725523C (en) * 2008-05-28 2017-01-10 Alcon Research, Ltd. Self-preserved emulsions
TWI544934B (en) 2008-06-09 2016-08-11 愛爾康研究有限公司 Improved pharmaceutical compositions containing a fluoroquinolone antibiotic drug
US8093352B2 (en) * 2008-08-05 2012-01-10 Alcon Research, Ltd. Polyalkylene oxide polyquaternary ammonium biocides
US8431751B1 (en) 2008-12-24 2013-04-30 Alcon Research, Ltd. Polymeric quaternary ammonium compounds with vicinal hydroxy groups
TW201038295A (en) * 2009-04-17 2010-11-01 Alcon Res Ltd Aqueous ophthalmic compositions containing anionic therapeutic agents
TWI489997B (en) * 2009-06-19 2015-07-01 Alcon Res Ltd Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI547522B (en) * 2009-07-07 2016-09-01 愛爾康研究有限公司 Ethyleneoxide butyleneoxide block copolymer compositions
MY150535A (en) 2009-09-22 2014-01-30 Coopervision Int Holding Co Lp Wettable hydrogel materials for use in ophthalmic applications and method
TWI478730B (en) 2009-12-03 2015-04-01 Alcon Res Ltd Ophthalmic emulsion
CN102939074A (en) * 2010-05-05 2013-02-20 爱尔康研究有限公司 Stabilized ophthalmic galactomannan formulations
WO2011153349A1 (en) 2010-06-02 2011-12-08 Alcon Research, Ltd. Ophthalmic compositions comprising pbo-peo-pbo block copolymers
US20110319502A1 (en) * 2010-06-25 2011-12-29 Coffey Martin J Compositions and Methods for Enhancing Reduction of Spore-Forming Microorganisms
MX2013000578A (en) 2010-07-21 2013-02-21 Alcon Res Ltd Pharmaceutical composition with enhanced solubility characteristics.
US8495971B2 (en) * 2010-12-08 2013-07-30 The Clorox Company Animal litter comprising a surfactant encapsulated fragrance nanoemulsion
CA2844791C (en) 2011-08-15 2016-12-06 John J. Matta Water soluble antimicrobial composition
US8324171B1 (en) 2012-02-06 2012-12-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US8664180B2 (en) 2012-02-06 2014-03-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US9693563B2 (en) 2013-08-20 2017-07-04 3M Innovative Properties Company Boron-silane polyether complex
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
TW201938141A (en) 2018-02-21 2019-10-01 瑞士商諾華公司 Lipid- based ophthalmic emulsion

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975536A (en) * 1971-05-12 1976-08-17 Fisons Limited Composition
US4029817A (en) * 1973-09-24 1977-06-14 Allergan Pharmaceuticals Soft contact lens preserving solutions
US4053628A (en) * 1971-05-12 1977-10-11 Fisons Limited Composition
US4410442A (en) * 1982-01-13 1983-10-18 The Procter & Gamble Company Disinfecting solutions for hydrophilic contact lenses
US4525346A (en) * 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4559186A (en) * 1981-10-05 1985-12-17 Ciba Geigy Corporation Production of borate crosslinked polyvinyl alcohol contact lenses
US4581379A (en) * 1976-03-11 1986-04-08 Nelson Research & Development Co. Contact lens preserving solution
US4675184A (en) * 1981-11-28 1987-06-23 501 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
US4710313A (en) * 1985-06-26 1987-12-01 Lion Corporation Detergent composition for contact lenses
US4748189A (en) * 1985-04-19 1988-05-31 Ciba-Geigy Corporation Ophthalmic solutions and methods for improving the comfort and safety of contact lenses
US4758595A (en) * 1984-12-11 1988-07-19 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2230358B2 (en) * 1973-05-25 1979-02-23 Fisons Ltd
SE419346B (en) 1978-02-24 1981-07-27 Opus Chemical Ab Process for the stabilization of bacteriological samples
US4470965A (en) * 1982-10-27 1984-09-11 Usv Pharmaceutical Corporation Celiprolol for the treatment of glaucoma
US4820352A (en) 1983-01-10 1989-04-11 Bausch & Lomb Incorporated Cleaning and conditioning solutions for contact lenses and methods of use
EP0209071B2 (en) * 1985-07-10 1998-07-15 Novartis AG Cleaning set for contact lenses
US5032392A (en) * 1986-09-04 1991-07-16 Vision Pharmaceuticals Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
JPH0696533B2 (en) 1987-01-14 1994-11-30 北陸製薬株式会社 Aqueous compositions of quinolone carboxylic acids
US5141665A (en) * 1987-03-31 1992-08-25 Sherman Laboratories, Inc. Cleaning, conditioning, storing and wetting system and method for rigid gas permeable contact lenses and other contact lenses
US5188826A (en) * 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
AT96022T (en) * 1989-08-03 1993-11-15 Eisai Co Ltd A process for the stabilization of photo augenspuelloesungen.
US5171526A (en) * 1990-01-05 1992-12-15 Allergan, Inc. Ophthalmic compositions and methods for preserving and using same
JP3058656B2 (en) * 1990-06-18 2000-07-04 トーメー産業株式会社 Cleaning or storage method of a contact lens using liquid composition and it contact lens
JPH0775620B2 (en) * 1991-04-08 1995-08-16 トーメー産業株式会社 Method for cleaning water-containing liquid composition for contact lenses and water-absorptive contact lens
FR2679773A1 (en) 1991-07-30 1993-02-05 Merck Sharp & Dohme Ophthalmic preparation containing an acceptable antimicrobial osmotic agent
DK0639070T4 (en) * 1992-05-06 2010-12-13 Alcon Lab Inc Use of borate-polyol complexes for ophthalmic preparations
US5505953A (en) * 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5494937A (en) * 1994-07-22 1996-02-27 Alcon Laboratories, Inc. Saline solution for treating contact lenses
US5603929A (en) * 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US6184189B1 (en) * 1995-06-07 2001-02-06 Alcon Laboratories, Inc. Liquid enzyme compositions and methods of use in contact lens cleaning and disinfecting systems
US5576278A (en) * 1995-06-07 1996-11-19 Alcon Laboratories, Inc. Stable liquid enzyme compositions and methods of use
US5604190A (en) * 1995-06-07 1997-02-18 Alcon Laboratories, Inc. Stable liquid enzyme compositions and methods of use in contact lens cleaning and disinfecting systems
US5672213A (en) * 1995-08-18 1997-09-30 Alcon Laboratories, Inc. Liquid enzyme compositions containing aromatic acid derivatives

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975536A (en) * 1971-05-12 1976-08-17 Fisons Limited Composition
US4053628A (en) * 1971-05-12 1977-10-11 Fisons Limited Composition
US4029817A (en) * 1973-09-24 1977-06-14 Allergan Pharmaceuticals Soft contact lens preserving solutions
US4581379A (en) * 1976-03-11 1986-04-08 Nelson Research & Development Co. Contact lens preserving solution
US4525346A (en) * 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4559186A (en) * 1981-10-05 1985-12-17 Ciba Geigy Corporation Production of borate crosslinked polyvinyl alcohol contact lenses
US4675184A (en) * 1981-11-28 1987-06-23 501 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
US4410442A (en) * 1982-01-13 1983-10-18 The Procter & Gamble Company Disinfecting solutions for hydrophilic contact lenses
US4758595A (en) * 1984-12-11 1988-07-19 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US4748189A (en) * 1985-04-19 1988-05-31 Ciba-Geigy Corporation Ophthalmic solutions and methods for improving the comfort and safety of contact lenses
US4710313A (en) * 1985-06-26 1987-12-01 Lion Corporation Detergent composition for contact lenses

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229219A1 (en) * 2005-04-11 2006-10-12 Advanced Medical Optics, Inc. Borate-polyol mixtures as a buffering system
US20070297990A1 (en) * 2006-06-27 2007-12-27 Shah Mandar V Self-preserving composition
US20100227003A1 (en) * 2006-06-27 2010-09-09 Mcneil-Ppc, Inc. Self-Preserving Compositions
US20080287672A1 (en) * 2007-05-16 2008-11-20 Uday Doshi Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods
US8609634B2 (en) 2007-05-16 2013-12-17 Mcneil-Ppc, Inc. Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods
US9579341B2 (en) 2007-05-16 2017-02-28 Johnson & Johnson Consumer Inc. Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods

Also Published As

Publication number Publication date
US20030130207A1 (en) 2003-07-10
US6849253B2 (en) 2005-02-01
US5505953A (en) 1996-04-09
US6365636B1 (en) 2002-04-02
US5811466A (en) 1998-09-22
US6503497B2 (en) 2003-01-07
US20020098160A1 (en) 2002-07-25
US6143799A (en) 2000-11-07

Similar Documents

Publication Publication Date Title
EP0999825B1 (en) Ophthalmic compositions containing galactomannan polymers and borate
US6479556B2 (en) Ophthalmic compositions for soft contact lens, method of enhancing wettability of soft contact lens and method of inhibiting terpenoid adsorption
US3954644A (en) Flexible contact lens cleaning, storing, and wetting compositions
US4525346A (en) Aqueous antimicrobial ophthalmic solutions
CA1311418C (en) Eyedrops
US6277365B1 (en) Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent
CA1186194A (en) Disinfecting solutions for hydrophilic contact lenses
US5756045A (en) Method and composition for disinfecting contact lenses
DE60117009T2 (en) Use of an aqueous solution for the treatment of dry eyes
KR100379881B1 (en) Conditioning solutions for hard contact lens care
EP0507816B1 (en) Ophthalmic compositions and methods for preserving and using same
CA2311660C (en) Multi-purpose contact lens care compositions
EP0371728B1 (en) Aqueous ophthalmic solutions and method for preserving same
JP2954356B2 (en) Conserved ophthalmic pharmaceutical compositions containing polymeric quaternary ammonium compound
US4046706A (en) Contact lens cleaning composition
CA2195087C (en) Saline solution for treating contact lenses
AU636698B2 (en) Improved conditioning solution for contact lenses and a method of using the same
EP0690728B1 (en) Preservative system for contact lens solutions
US5037647A (en) Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US6872705B2 (en) Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
US5597559A (en) Ophthalmic formulation
AU721273B2 (en) Method and composition for rewetting contact lenses and relieving eye dryness
CA1259542A (en) Disinfecting and preserving solutions for contact lenses and methods of use
US9492581B2 (en) Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
EP1339386B1 (en) Reversible gelling system for ocular drug delivery

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION